Health Canada is reconsidering how they deal with some of the recognized medical treatments that fall outside of the scope of approved Canadian therapies. The Special Access Program (SAP) allows for pharmaceutical options that would otherwise be unavailable to Canadian residents, ; when conventional therapies have failed, are unsuitable, or are unavailable.
The SAP lives in Part C of the Food and Drug Regulations (FDR). In 2013, it was amended to exclude restricted drugs (i.e. Part J of the FDR – controlled substances); including psilocybin, MDMA, LSD, DMT, and their analogs.
Health Canada is allowing a period of community input on the current state of the SAP, ending on February 10, 2021.
Share this post
